<DOC>
	<DOCNO>NCT02303405</DOCNO>
	<brief_summary>A 4-month , randomize , prospective , open-label comparison trial hydroxychloroquine vs. pioglitazone type 2 diabetic patient inadequately control maximally tolerate dos metformin plus sulfonylurea .</brief_summary>
	<brief_title>Hydroxychloroquine Versus Pioglitazone Combination Treatment Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>A 4-month , randomize , prospective , open-label comparison trial 4 month hydroxychloroquine vs. pioglitazone type 2 diabetic patient inadequately control maximally tolerate dos metformin plus sulfonylurea .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Male female , age 1875 , inclusive Known type 2 diabetes ( diagnose accord 1997 ADA diagnostic criterion ) At least 3 month treatment maximum tolerate dos metformin sulfonylurea Hemoglobin A1c ≥ 7.5 % &lt; 11.0 % Body mass index ( BMI ) &lt; 45 kg/m2 Able comply schedule visit requirement protocol Any contraindication use metformin sulfonylurea Extreme hyperglycemia ( FPG ≥ 300 mg/dL ) , symptoms polyuria polydipsia , Hemoglobin A1c ≥ 11.0 % Current use insulin ; history clinical suspicion type 1 diabetes mellitus Symptomatic hypoglycemia occur average frequency &gt; per day Highly erratic dietary schedule , extremely food insecure household , homelessness may adversely affect good glycemic control , judge investigator Occupations involve regular operation motor vehicle heavy machinery may pose hazard event unanticipated blurred vision Known history Class III IV heart failure , cardiac arrhythmia , severe peripheral edema , advanced osteoporosis , document bladder malignancy , intolerance pioglitazone Known history collagen vascular disorder , glucose6phosphate dehydrogenase deficiency , hematologic disorder , psoriasis , know intolerance hydroxychloroquine Known history preproliferative proliferative retinopathy , clinically significant retinal abnormality note patient 's recent ( i.e. , within 1 year ) ophthalmologic exam ; subject receive routine annual ophthalmologic surveillance diabetic retinopathy within past year must annual surveillance perform screen An estimate GFR ( Modification Diet Renal Disease ( MDRD ) formula ) &lt; 45 mL/min , history nephrotic syndrome ( define spot urine proteincreatinine ratio &gt; 3500 mg per g urine creatinine ) Subjects active hemoglobin abnormality render Hemoglobin A1c measurement unreliable History clinically significant hepatic , cardiovascular , infectious , dermatologic , psychiatric , major systemic disease , opinion investigator , may make use pioglitazone hydroxychloroquine unsafe , otherwise make interpretation data difficult . Female subject childbearing potential sexually active use reliable form contraception agree use reliable form contraception . Reliable form contraception include systemic contraceptive ( oral , implant injection ) , diaphragm spermicide , cervical cap , IUD , condom spermicide . Current pregnancy lactation . Subjects likely require initiate therapy drug may interfere glucose metabolism course study ( e.g. , glucocorticoid ) . Subjects another investigational study receive another investigational medication within 30 day study entry Subjects unable unwilling give inform consent , comply component study protocol , attend schedule followup visit , present barrier would make implementation protocol unusually difficult .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Glucose Control</keyword>
	<keyword>Inflammation</keyword>
</DOC>